吉利德科学在盘前交易中大涨5.06%,引发了市场的广泛关注。消息面上,吉利德科学公布了2024年第四季度财报,表现优异。
财报显示,吉利德科学第四季度营收同比增长6%至75.69亿美元,超过分析师预期的71.4亿美元。其中,公司的核心产品艾滋病药物销售额同比大增16%至55亿美元,为营收增长的主要动力。
此外,吉利德科学第四季度纯利润同比增长25%至17.83亿美元,每股收益1.9美元也超出市场预期的1.7美元。公司对2025年的业绩也持乐观态度,预计全年销售额将达282亿至286亿美元,调整后每股收益在7.7美元至8.1美元区间,均略高于分析师的平均预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.